文献速递肝病

代谢功能障碍相关脂肪性肝病及相关共病对混合型MASLD-2型糖尿病队列认知与健康相关生活质量结局的影响

Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohort.
PubMed 文献 · Am J Gastroenterol · 2025-06-11

研究纳入601例超重/肥胖的MASLD和/或2型糖尿病患者,用瞬时弹性成像和受控衰减参数评估肝脏脂肪变与硬度,用RBANS和SF-36评估认知与健康相关生活质量。结果显示严重脂肪变(CAP≥300 dB/m)与认知损害相关(OR 1.42,95%CI 1.0-2.0,P=0.045),显著或高肝硬度(LS≥8 kPa)与更高躯体受限相关(OR 1.9,95%CI 1.1-3.2,P=0.019)。

要点

  • 严重脂肪变(CAP≥300 dB/m,n=378)者中位认知评分落入异常范围(P=0.056)。
  • CAP≥300 dB/m与认知损害显著相关(OR 1.42,95%CI 1.0-2.0,P=0.045)。
  • LS≥8 kPa(n=69)与更高躯体受限相关(OR 1.9,95%CI 1.1-3.2,P=0.019)。

核心结论

  • MASLD严重程度与认知功能及健康相关生活质量受损相关,体现其多因素性质。
  • 严重肝脂肪变可能是认知下降的危险因素,而显著或高肝硬度似乎显著影响健康相关生活质量。

研究设计与样本

  • 共纳入601例超重/肥胖的MASLD和/或2型糖尿病患者。
  • 用瞬时弹性成像评估肝硬度,用受控衰减参数(CAP)评估脂肪变。
  • 用重复性成套神经心理状态测验(RBANS)和SF-36问卷评估认知功能与健康相关生活质量。

主要发现

  • 严重脂肪变(CAP≥300 dB/m,n=378)患者中位认知评分落入异常范围(P=0.056)。
  • CAP≥300 dB/m者较CAP<300 dB/m者躯体功能(P<0.001)、活力(P=0.011)、总体健康(P=0.001)和即刻记忆(P=0.034)评分显著更低,视空间/建构评分有更低趋势(P=0.058)。
  • 显著或高肝硬度(LS≥8 kPa,n=69)者较LS<8 kPa者躯体功能更低(P<0.001)、躯体受限更高(P=0.004)、总体健康更差(P=0.011)。
  • 多因素校正分析中,CAP≥300 dB/m与认知损害显著相关(OR 1.42,95%CI 1.0-2.0,P=0.045)。
  • 多因素校正分析中,LS≥8 kPa与更高躯体受限相关(OR 1.9,95%CI 1.1-3.2,P=0.019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with multiple comorbidities that contribute to impaired vascular function, worsening cognitive impairment, and quality of life. The aim of this study was to evaluate the impact of MASLD and related comorbidities on cognitive function and health-related quality of life (HRQoL). METHODS: A total of 601 overweight/obese patients with MASLD and/or type 2 diabetes mellitus were included. Liver stiffness (LS) measurement and steatosis were assessed by transient elastography and controlled attenuation parameter (CAP), respectively. Cognitive function and HRQoL were evaluated using the Repeatable Battery for the Assessment of Neuropsychological Status and Short Form (36) Health Survey (SF-36) questionnaires. RESULTS: MASLD-related comorbidities were found to significantly and clinically affect cognitive function and HRQoL. Patients with severe steatosis (CAP ≥ 300 dB/m, n = 378) exhibited median cognitive scores falling into the abnormal range ( P = 0.056), with statistically significant lower scores in physical functioning ( P < 0.001), vitality ( P = 0.011), general health ( P = 0.001), and immediate memory ( P = 0.034), as well as a trend toward lower visuospatial/construction scores ( P = 0.058) than CAP <300 dB/m. Among patients with significant or high LS (LS ≥ 8 kPa, n = 69), lower physical functioning ( P < 0.001), higher physical limitations ( P = 0.004), and worse general health ( P = 0.011) were observed compared with those with LS < 8 kPa. In the multivariate adjusted analyses, CAP ≥ 300 dB/m was significantly associated with cognitive impairment (odds ratio: 1.42, 95% confidence interval 1.0; 2.0, P = 0.045), whereas LS ≥ 8 kPa was associated with higher physical limitations (odds ratio: 1.9, 95% confidence interval 1.1; 3.2, P = 0.019). DISCUSSION: Our findings highlight the relationship between MASLD severity and impairment in cognitive function and HRQoL, underscoring its multifactorial nature. Specifically, severe hepatic steatosis may be a risk factor of cognitive decline, whereas significant or high LS seems to greatly affect HRQoL.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Perez-Diaz-Del-Campo N, Castelnuovo G, Ferro A, et al. Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohort. Am J Gastroenterol. 2025. PMID: 40498052. doi:10.14309/ajg.0000000000003594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。